MX2020002247A - Derivado de gnrh de conjugado a ácido palmítico de larga duración y composición farmacéutica que lo contiene. - Google Patents
Derivado de gnrh de conjugado a ácido palmítico de larga duración y composición farmacéutica que lo contiene.Info
- Publication number
- MX2020002247A MX2020002247A MX2020002247A MX2020002247A MX2020002247A MX 2020002247 A MX2020002247 A MX 2020002247A MX 2020002247 A MX2020002247 A MX 2020002247A MX 2020002247 A MX2020002247 A MX 2020002247A MX 2020002247 A MX2020002247 A MX 2020002247A
- Authority
- MX
- Mexico
- Prior art keywords
- gnrh
- derivative
- pharmaceutical composition
- composition containing
- palmitic acid
- Prior art date
Links
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 title abstract 4
- 235000021314 Palmitic acid Nutrition 0.000 title abstract 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 title 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 title 1
- 230000007774 longterm Effects 0.000 title 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 5
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 2
- 239000002434 gonadorelin derivative Substances 0.000 abstract 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000003405 delayed action preparation Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003163 gonadal steroid hormone Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a un derivado de la hormona liberadora de gonadotropina (GnRH) conjugado a ácido palmítico de larga duración y una composición farmacéutica que lo contiene. Se espera que un derivado de GnRH de la presente invención contribuya bastante, a través de excelente biodisponibilidad y vida media incrementada en la sangre, a la reducción en frecuencia de dosificación de fármacos y dosis y similares en el tratamiento de las enfermedades dependientes a la hormona sexual. Particularmente, el derivado de GnRH puede solucionar las desventajas de las preparaciones de liberación sostenida de GnRH existentes, las cuales tienen los efectos laterales de sensación residual y dolor en el sitio de inyección.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170125291 | 2017-09-27 | ||
| PCT/KR2018/006954 WO2019066199A1 (ko) | 2017-09-27 | 2018-06-20 | 지속형 팔미트산 결합 GnRH 유도체 및 이를 포함하는 약제학적 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020002247A true MX2020002247A (es) | 2021-03-25 |
| MX380887B MX380887B (es) | 2025-03-12 |
Family
ID=65903631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002247A MX380887B (es) | 2017-09-27 | 2018-06-20 | Derivado de gnrh de conjugado a ácido palmítico de larga duración y composición farmacéutica que lo contiene. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10994018B2 (es) |
| EP (1) | EP3639856B1 (es) |
| JP (1) | JP6800372B2 (es) |
| KR (2) | KR102072164B1 (es) |
| CN (1) | CN111093709B (es) |
| AU (1) | AU2018338924B2 (es) |
| CA (1) | CA3075252C (es) |
| ES (1) | ES2925946T3 (es) |
| MX (1) | MX380887B (es) |
| RU (2) | RU2746566C2 (es) |
| WO (1) | WO2019066199A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020196946A1 (ko) | 2019-03-26 | 2020-10-01 | 노벨파마 주식회사 | 지속형 지방산 결합 GnRH 유도체 및 이를 포함하는 약제학적 조성물 |
| KR102020788B1 (ko) | 2019-03-29 | 2019-09-11 | 위월드 주식회사 | 다수의 위성 환경에서의 위성 추적 안테나 시스템 및 이를 이용한 위성 추적 방법 |
| KR102628523B1 (ko) * | 2020-06-30 | 2024-01-24 | 주식회사 종근당 | GnRH 유도체를 포함하는 주사용 조성물 |
| CN115671255A (zh) * | 2022-10-20 | 2023-02-03 | 中国科学院深圳先进技术研究院 | 醋酸德舍瑞林在制备调节动物的性周期药物中的应用 |
| WO2026068660A1 (en) * | 2024-09-26 | 2026-04-02 | Ferring B.V. | Lipidated gonadotropin releasing hormone analogues |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1045625A (ja) | 1996-04-30 | 1998-02-17 | Takeda Chem Ind Ltd | 医薬組成物 |
| AU2407997A (en) | 1996-04-30 | 1997-11-19 | Takeda Chemical Industries Ltd. | Combined use of gnrh agonist and antagonist |
| US6565874B1 (en) * | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| BRPI0314546B8 (pt) | 2002-09-27 | 2021-05-25 | Zentaris Gmbh | composição de gel farmacêutico compreendendo peptídeos farmaceuticamente atvos com liberação sustentada, método para a produção dos mesmos kit. |
| AU2004313245B2 (en) * | 2003-12-30 | 2011-04-14 | Durect Corporation | Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH |
| WO2005116058A1 (en) * | 2004-05-27 | 2005-12-08 | Curepeptide Ltd. | Peptides useful for treating gnrh associated diseases |
| RU2325160C1 (ru) * | 2006-07-31 | 2008-05-27 | Ефаг АО | Средство для лечения рака предстательной железы и профилактики его рецидива |
| BRPI0918820A2 (pt) | 2008-08-29 | 2016-06-14 | Genzyme Corp | formulações de peptídeo de liberação controlada e métodos, para aumento de eficiência de carga e para modulação das taxas de liberação por erosão e de difusão inicial, de um agente bioativo em um sistema de liberação baseado em polímero |
| WO2011148384A1 (en) * | 2010-05-07 | 2011-12-01 | Matrix Laboratories Ltd | Novel process for the preparation of leuprolide and its pharmaceutically acceptable salts thereof |
| WO2012138867A2 (en) | 2011-04-07 | 2012-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Long-acting peptide analogs |
| KR101586789B1 (ko) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| KR101586791B1 (ko) * | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| EP2832361A1 (en) * | 2013-07-29 | 2015-02-04 | Ipsen Pharma S.A.S. | Aqueous sustained release compositions of LHRH analogs |
| US9150615B2 (en) * | 2013-12-18 | 2015-10-06 | Scinopharm Taiwan, Ltd. | Process for the preparation of leuprolide and its pharmaceutically acceptable salts |
| CN105797134B (zh) * | 2016-03-29 | 2019-06-14 | 浙江圣兆药物科技股份有限公司 | 一种难溶亮丙瑞林缓释制剂 |
-
2018
- 2018-06-20 US US16/630,704 patent/US10994018B2/en active Active
- 2018-06-20 WO PCT/KR2018/006954 patent/WO2019066199A1/ko not_active Ceased
- 2018-06-20 RU RU2020109232A patent/RU2746566C2/ru active
- 2018-06-20 RU RU2020104475A patent/RU2020104475A/ru unknown
- 2018-06-20 KR KR1020180070866A patent/KR102072164B1/ko active Active
- 2018-06-20 CA CA3075252A patent/CA3075252C/en active Active
- 2018-06-20 AU AU2018338924A patent/AU2018338924B2/en not_active Ceased
- 2018-06-20 ES ES18862614T patent/ES2925946T3/es active Active
- 2018-06-20 EP EP18862614.7A patent/EP3639856B1/en active Active
- 2018-06-20 JP JP2020511372A patent/JP6800372B2/ja active Active
- 2018-06-20 MX MX2020002247A patent/MX380887B/es unknown
- 2018-06-20 CN CN201880058702.1A patent/CN111093709B/zh active Active
-
2020
- 2020-01-23 KR KR1020200009354A patent/KR20200011535A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3639856A1 (en) | 2020-04-22 |
| KR102072164B1 (ko) | 2020-02-03 |
| RU2020109232A (ru) | 2020-04-20 |
| AU2018338924B2 (en) | 2020-05-21 |
| US20200268896A1 (en) | 2020-08-27 |
| JP2020528070A (ja) | 2020-09-17 |
| KR20190036449A (ko) | 2019-04-04 |
| ES2925946T3 (es) | 2022-10-20 |
| EP3639856B1 (en) | 2022-08-03 |
| CA3075252A1 (en) | 2019-04-04 |
| RU2746566C2 (ru) | 2021-04-15 |
| CN111093709A (zh) | 2020-05-01 |
| US10994018B2 (en) | 2021-05-04 |
| AU2018338924A1 (en) | 2020-02-06 |
| CA3075252C (en) | 2020-12-08 |
| JP6800372B2 (ja) | 2020-12-16 |
| KR20200011535A (ko) | 2020-02-03 |
| RU2020109232A3 (es) | 2020-10-16 |
| WO2019066199A1 (ko) | 2019-04-04 |
| CN111093709B (zh) | 2021-11-12 |
| EP3639856A4 (en) | 2021-03-10 |
| RU2020104475A (ru) | 2021-08-02 |
| MX380887B (es) | 2025-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020002247A (es) | Derivado de gnrh de conjugado a ácido palmítico de larga duración y composición farmacéutica que lo contiene. | |
| CY1124532T1 (el) | Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tf | |
| EA201790568A1 (ru) | Применение двойного агониста рецепторов glp-1/глюкагона пролонгированного действия для лечения неалкогольной жировой болезни печени | |
| EA201590847A1 (ru) | Новые ингибиторы rock | |
| ZA202406617B (en) | Insulin containing pharmaceutical compositions | |
| EA201792592A1 (ru) | Фармацевтические препараты, содержащие тенофовир и эмтрицитабин | |
| EA202090573A1 (ru) | Составы нирапариба | |
| EA033456B1 (ru) | Конъюгаты антитело-лекарственное средство, содержащие пептидомиметические линкеры | |
| EA201691023A1 (ru) | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством | |
| EA201590622A1 (ru) | Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения | |
| CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
| EA201890654A1 (ru) | Терапевтические композиции для лечения вируса иммунодефицита человека | |
| EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
| EA201792591A1 (ru) | Фармацевтические препараты | |
| EA201291089A1 (ru) | Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций | |
| EA201590697A1 (ru) | Производные кетамина | |
| EA201590797A1 (ru) | Препараты с модифицированным высвобождением опрозомиба | |
| FI3383385T4 (fi) | Melflufeeniannoskuureja syöpään | |
| PE20221168A1 (es) | Agonistas del receptor npy2 | |
| MX2019001032A (es) | Formulacion que tiene caracteristicas mejoradas de liberacion de farmacos ph dependientes, que contienen esomeprazol o una de sus sales farmaceuticas aceptable. | |
| EA201491427A1 (ru) | Замещенные фенилимидазопиразолы и их применение | |
| EA201500506A1 (ru) | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16a | |
| RU2013108390A (ru) | Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека | |
| EA202090666A1 (ru) | Применение содержащей бензоат композиции для лечения глициновой энцефалопатии | |
| MX2020013206A (es) | Derivados de gnrh conjugados con acidos grasos de accion prolongada y composiciones farmaceuticas que contienen los mismos. |